# US 2015/0307851 A1 · Influenza viruses with mutant pb2 gene segment as live attenuated vaccines

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0307851 A1
- Document ID: US20150307851A1
- Status: Published application
- Kind: A1
- Application number: 14/699,213
- Filed: 2015-04-29
- Published: 2015-10-29
- Earliest claimed: 2011-08-26
- Assignees: Wisconsin Alumni Research Foundation (WARF)
- Applicants: Wisconsin Alumni Research Foundation (WARF)
- Inventors: Yoshihiro Kawaoka; Gabriele Neumann; Makoto Ozawa
- Web page: https://patentgrep.com/patent/US20150307851A1

## CPC

- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 35/76: Viruses; Subviral particles; Bacteriophages
- A61K 39/092: {Streptococcus}
- A61K 39/12: Viral antigens
- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- A61P 31/16: for influenza or rhinoviruses
- G01N 33/56983: {Viruses}
- A61K 2039/5252: {inactivated (killed)}
- A61K 2039/5254: {avirulent or attenuated}
- A61K 2039/5256: {expressing foreign proteins}
- A61K 2039/543: {intranasal}
- A61K 2039/70: {Multivalent vaccine}
- C12N 2760/16121: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16143: viral genome or elements thereof as genetic vector
- C12N 2760/16151: Methods of production or purification of viral material
- C12N 2760/16171: Demonstrated in vivo effect
- G01N 2333/11: Orthomyxoviridae, e.g. influenza virus
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The invention provides a recombinant biologically contained influenza virus that is a PB2 knockout virus, e.g., one that is useful to generate a multivalent vaccine, and methods of making and using that virus.

## Claims

### Claim 1

(canceled)

### Claim 2

A vaccine comprising an effective amount of an isolated stable, biologically contained multivalent influenza virus comprising: i) 8 different gene segments including a PA viral gene segment, a PB1 viral gene segment, a mutant PB2 viral gene segment, a HA viral gene segment, a NA viral gene segment, a NP viral gene segment, a M (M1 and M2) viral gene segment, and a NS (NS1 and NS2) viral gene segment, ii) 8 different gene segments including a PA viral gene segment, a PB1 viral gene segment, a mutant PB2 viral gene segment, a HA viral gene segment, a NA (NA and NB) viral gene segment, a NP viral gene segment, a M (M1 and BM2) viral gene segment and a NS (NS1 and NS2) viral gene segment, or iii) 7 different gene segments including a PA viral gene segment, a PB 1 viral gene segment, a mutant PB2 viral gene segment, a HEF viral gene segment, a NP viral gene segment, a M (M1 and CM2) viral gene segment, and a NS (NS1 and NS2) viral gene segment;
wherein the mutant PB2 viral gene segment includes 5′ and 3′ incorporation sequences including 3′ or 5′ coding and non-coding incorporation sequences flanking a heterologous nucleotide sequence and does not include contiguous sequences corresponding to sequences encoding a functional PB2, and wherein the heterologous nucleotide sequence encodes a heterologous protein.

### Claim 3 (depends on 2)

The vaccine of claim 2 wherein the heterologous protein comprises an influenza virus HA protein or an influenza NA protein from a different strain than the HA encoded by the HA viral gene segment or the NA encoded by the NA viral gene segment.

### Claim 4 (depends on 2)

The vaccine of claim 2 wherein the heterologous protein comprises a protein of a bacterium, yeast, fungus, or a virus that is not an influenza virus.

### Claim 5 (depends on 2)

The vaccine of claim 2 wherein the heterologous protein comprises a cancer associated antigen.

### Claim 6 (depends on 2)

The vaccine of claim 2 wherein the heterologous nucleotide sequence is flanked by about 3 to about 400 nucleotides of the 5′ and/or 3′ PB2 coding region adjacent to non-coding sequence.

### Claim 7 (depends on 2)

The vaccine of claim 2 wherein the gene segments for HA and NA are from a different isolate that the PA, PB1, PB2, NP, NS, and M gene segments.

### Claim 8 (depends on 2)

A method to immunize a vertebrate, comprising: contacting the vertebrate with the vaccine of claim 2.

### Claim 9 (depends on 8)

The method of claim 8 wherein the vertebrate is an avian or a mammal.

### Claim 10

A method to prepare a biologically contained, multivalent 8 segment influenza A or B virus, comprising contacting a host cell with one or more vectors which include transcription cassettes for vRNA production and transcription cassettes for mRNA production, wherein the transcription cassettes for vRNA production are a transcription cassette comprising a PolI promoter operably linked to an influenza virus PA DNA in an orientation for vRNA production linked to a PolI transcription termination sequence, a transcription cassette comprising a PolI promoter operably linked to an influenza virus PB1 DNA in an orientation for vRNA production linked to a PolI transcription termination sequence, a transcription cassette comprising a PolI promoter operably linked to a mutant influenza virus PB2 DNA in an orientation for vRNA production linked to a PolI transcription termination sequence, a transcription cassette comprising a PolI promoter operably linked to an influenza virus HA DNA in an orientation for vRNA production linked to a PolI transcription termination sequence, a transcription cassette comprising a PolI promoter operably linked to an influenza virus NA DNA in an orientation for vRNA production linked to a PolI transcription termination sequence, a transcription cassette comprising a PolI promoter operably linked to an influenza virus NP DNA in an orientation for vRNA production linked to a PolI transcription termination sequence, a transcription cassette comprising a PolI promoter operably linked to an influenza virus M DNA in an orientation for vRNA production linked to a PolI transcription termination sequence, and a transcription cassette comprising a PolI promoter operably linked to an influenza virus NS (NS1 and NS2) DNA in an orientation for vRNA production linked to a PolI transcription termination sequence, wherein the mutant PB2 DNA includes 5′ and 3′ incorporation sequences including 3′ or 5′ coding and non-coding incorporation sequences flanking a heterologous nucleotide sequence and does not include contiguous sequences corresponding to sequences that encode a functional PB2, and wherein the heterologous nucleotide sequence encodes a heterologous protein;
and wherein the transcription cassettes for mRNA production are a transcription cassette comprising a PolI promoter operably linked to a DNA coding region for influenza virus PA linked to a PolI transcription termination sequence, a transcription cassette comprising a PolI promoter operably linked to a DNA coding region for influenza virus PB1 linked to a PolI transcription termination sequence, and a transcription cassette comprising a PolII promoter operably linked to a DNA coding region for influenza virus NP linked to a PolII transcription termination sequence, wherein the genome of host cell is stably augmented with a transcription cassette comprising a PolII promoter operably linked to a DNA coding region for influenza virus PB2 linked to a PolII transcription termination sequence, and wherein the host cell does not comprise sequences corresponding to PB2 coding sequences for vRNA production of a wild-type PB2 gene segment; and isolating the biologically contained virus from the host cell.

### Claim 11 (depends on 10)

The method of claim 10 wherein the heterologous protein comprises an influenza virus HA protein or an influenza NA protein from a different strain than the HA encoded by the HA viral gene segment or the NA encoded by the NA viral gene segment.

### Claim 12 (depends on 10)

The method of claim 10 wherein the heterologous protein comprises a protein of a bacterium, yeast, fungus, or a virus that is not an influenza virus, or comprises a cancer associated antigen.

### Claim 13 (depends on 9)

The method of claim 9 wherein the HA is a type A HA.

### Claim 14 (depends on 9)

The method of claim 9 wherein the cell is a 293 cell, a 293T cell, a DF-1 cell, a A549 cell, a Vero cell or a MDCK cell.

### Claim 15

A method to prepare a biologically contained, multivalent 8 segment influenza A or B virus, comprising contacting a host cell with one or more vectors which include transcription cassettes for vRNA production and transcription cassettes for mRNA production, wherein the transcription cassettes for vRNA production are a transcription cassette comprising a PolI promoter operably linked to an influenza virus PA DNA in an orientation for vRNA production linked to a PolI transcription termination sequence, a transcription cassette comprising a PolI promoter operably linked to an influenza virus PB1 DNA in an orientation for vRNA production linked to a PolI transcription termination sequence, a transcription cassette comprising a PolI promoter operably linked to a mutant influenza virus PB2 DNA in an orientation for vRNA production linked to a PolI transcription termination sequence, a transcription cassette comprising a PolI promoter operably linked to an influenza virus HA DNA in an orientation for vRNA production linked to a PolI transcription termination sequence, a transcription cassette comprising a PolI promoter operably linked to an influenza virus NA DNA in an orientation for vRNA production linked to a PolI transcription termination sequence, a transcription cassette comprising a PolI promoter operably linked to an influenza virus NP DNA in an orientation for vRNA production linked to a PolI transcription termination sequence, a transcription cassette comprising a PolI promoter operably linked to an influenza virus M DNA in an orientation for vRNA production linked to a PolI transcription termination sequence, and a transcription cassette comprising a PolI promoter operably linked to an influenza virus NS (NS1 and NS2) DNA in an orientation for vRNA production linked to a PolI transcription termination sequence, wherein the mutant PB2 DNA includes 5′ and 3′ incorporation sequences including 3′ or 5′ coding and non-coding incorporation sequences flanking a heterologous nucleotide sequence and does not include contiguous sequences corresponding to sequences that encode a functional PB2, and wherein the heterologous nucleotide sequence encodes a heterologous protein; and wherein the transcription cassettes for mRNA production are a transcription cassette comprising a PolII promoter operably linked to a DNA coding region for influenza virus PA linked to a PolII transcription termination sequence, a transcription cassette comprising a PolII promoter operably linked to a DNA coding region for influenza virus PB1 linked to a PolII transcription termination sequence, and a transcription cassette comprising a PolII promoter operably linked to a DNA coding region for influenza virus NP linked to a PolII transcription termination sequence, wherein the genome of host cell is stably augmented with a transcription cassette comprising a PolII promoter operably linked to a DNA coding region for influenza virus PB2 linked to a PolII transcription termination sequence, and wherein the host cell does not comprise sequences corresponding to PB2 coding sequences for vRNA production of a wild-type PB2 gene segment; and isolating the biologically contained virus from the host cell, wherein the cell is contacted with the vector for mRNA production of PB2 before the other vectors.

### Claim 16 (depends on 15)

The method of claim 15 wherein the heterologous protein comprises an influenza virus HA protein or an influenza NA protein from a different strain than the HA encoded by the HA viral gene segment or the NA encoded by the NA viral gene segment.

### Claim 17 (depends on 15)

The method of claim 15 wherein the heterologous protein comprises a protein of a bacterium, yeast, fungus, or a virus that is not an influenza virus, or comprises a cancer associated antigen.

### Claim 18 (depends on 15)

The method of claim 15 wherein the heterologous protein is a glycoprotein.

### Claim 19 (depends on 15)

The method of claim 15 wherein the HA is a type A HA.

### Claim 20 (depends on 15)

The method of claim 15 wherein the biologically contained virus is a 6:2 reassortant.

### Claim 21 (depends on 15)

The method of claim 15 wherein the cell is a 293 cell, a 293T cell, a DF-1 cell, a A549 cell, a Vero cell or a MDCK cell.
